Yuko Mizuma – GM, Hong Kong & Macau, Eli Lilly Asia, Inc.
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
Address: 43rd Floor, Gloucester Tower, The Landmark, 15 Queen’s Road Central, Hong Kong
Tel: +852 2218 9100
Web: http://www.orrick.com/Offices/Hong-Kong/Pages/default.aspx
Hong Kong is uniquely positioned at the doorsteps of the world’s fastest growing major economy of the 21st century and the lawyers on Orrick’s China Team have been there since the first days those doors were opened. In 1972, Coudert Brothers was the first foreign law firm to open an office in Hong Kong and, in November 2005, the entire 25-lawyer office of Coudert joined Orrick, opening Orrick’s first of three China-focused offices. Orrick’s offices in Beijing and Shanghai opened in 2006 when most of Coudert’s lawyers in Beijing and Shanghai also joined Orrick. In addition to being first in Hong Kong, Coudert was the first foreign law firm to establish a permanent presence in Beijing (1979), the first foreign law firm to be approved by the Ministry of Justice to establish a law office in China (Beijing, 1992; with the receipt of license no. 001) and one of the first foreign law firms to open an office in Shanghai (2001).
For more than three decades, Orrick’s Hong Kong lawyers have been guiding the world’s most prominent businesses through many of the first and most complex commercial and financial transactions involving China, including:
* The Coca-Cola Company
* McDonald’s
* S.C. Johnson & Sons, Inc.
* Carrefour
* General Motors Corporation
* NEC Corporation
* Occidental Petroleum
Beyond China, the Hong Kong team’s experience extends throughout the Asia-Pacific region on significant transactions including the “London Club” of more than 60 commercial banks in a series of jumbo loans of more than $1.5 billion of U.S. dollar- and yen-denominated sovereign debt extended to the Republic of Indonesia; Telenor Ltd. (a Norwegian telecommunications company) in acquiring shares in two Thai telecommunications companies; foreign investors in a series of acquisitions and divestitures in the electric power generating sector in the Philippines; and structuring and advising many of the first hedge funds and private equity funds organized with investors from multiple jurisdictions for investment targets throughout the Asia-Pacific region.
International Reputation
The reputation of Orrick’s Hong Kong lawyers is well recognized by recent awards from leading global publications, including:
* M&A Deal of the Year
* Real Estate and Construction Deal of the Year
* Logistics Deal of the Year
Unique Qualifications
Orrick’s Hong Kong team is strongly positioned to assist local and international clients with sophisticated transactions that cross multiple jurisdictions. Orrick’s Hong Kong office provides clients with a unique combination of lawyers who are qualified in multiple jurisdictions, fluent in multiple languages, graduates of many of the world’s most well respected legal and business universities, experienced in business operations and management, and have served in government positions.
* Multiple Jurisdictions
Orrick’s Hong Kong lawyers have more than 30 years of experience handling corporate, commercial, securities, finance, litigation and arbitration matters under the laws of the multiple jurisdictions where local lawyers are qualified – Hong Kong, Australia, the United States, England and Wales.
* Multiple Language Capabilities
In addition to being qualified to practice in multiple jurisdictions, Orrick’s Hong Kong office also provides clients with lawyers who are fluent in multiple languages, including English, Cantonese, French, Korean, Mandarin and Putonghua.
* Legal Educations and Business Backgrounds
Lawyers in Orrick’s Hong Kong office have received graduate degrees (J.D./LL.B., LL.M., M.B.A., B.A. and B.S.) from well-known universities in the United States, the United Kingdom, Australia, China and Hong Kong, including Chinese University of Hong Kong, Columbia University, Fudan University (Shanghai), Harvard Law School, London School of Economics, New York Law School, Stanford Law School, University of California (Berkeley), University of Hong Kong, University of Melbourne, University of New South Wales, University of Southern California (Los Angeles), University of International Business and Economics (Beijing) and Yale College.
Orrick’s team of lawyers also includes lawyers with diverse backgrounds, including a lawyer who began advising foreign companies on China matters in 1980 as a Beijing-based business representative and consultant, a lawyer who practiced in California and Korea before moving to Hong Kong in 1993, a lawyer who worked for the Department of Justice of the Hong Kong Government, and a lawyer who held numerous Shenzhen-based management positions. The Hong Kong office is also staffed by Chinese and foreign consultants, legal assistants, trainee solicitors and translators.
Banking and Bank Regulatory Matters, Dispute Resolution, Emerging Companies and Venture Capital, Employment Law, Finance and Project Finance, Financial Markets, Intellectual Property, Internal Investigations, Life Sciences, Media and Entertainment, Mergers and Acquisitions, Private Equity, Investment Funds and Venture Capital, Real Estate Development and Finance, Restructuring, Securities, Tax
Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses…
Drawing on an extensive management background in telecom, IT, and digital, Vincent Ma now serves as CEO of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP). He outlines the under-construction…
Johnson & Johnson Innovative Medicine veteran and general manager of the company’s Hong Kong & Macau affiliate SunKeun Huh explains J&J Hong Kong’s strong position in schizophrenia and its significant oncology…
OASES was established to position Hong Kong as a global innovation and technology hub, with significant investments in infrastructure and funding, particularly focusing on life and health sciences, AI, fintech,…
One year since our last conversation, the Hong Kong Institute of Biotechnology’s Gina Jiang introduces the significant strides made in setting up a GMP facility for CAR-T cell therapy manufacturing…
A surgeon by training, Prof Philip Chiu is now dean of the Faculty of Medicine at the research-focused Chinese University of Hong Kong (CUHK). He shares the creation of CUHK’s…
The City University of Hong Kong (CityUHK) has a well-earned reputation as an innovative hub for research and professional education. Michael Yang, Senior VP of Innovation and Enterprise, professor of…
Andrea Chang, general manager of Eisai Hong Kong explains the importance of the firm’s FDA-approved Biogen-partnered Alzheimer’s disease (AD) product, particularly in Hong Kong where some 20 percent of the…
Dr Juliana Chan, one of Asia’s leading endocrinologists, is also the founding director of GemVCare, a company that provides data to medical professionals to advise patients on diabetes prevention, diagnosis, and…
Immuno Cure has a unique approach to the failure-ridden field of HIV vaccine development: focusing on a therapeutic vaccine for already infected individuals rather than a preventive vaccine. Founders Tom…
Arbele is a clinical stage biotech centred on an innovative T-Cell Engager approach to gastrointestinal cancers. Chairman and founder John Luk explains the prevalence of these cancers in China, the…
Sabrina Chan, senior executive director of the Hong Kong Association of the Pharmaceutical Industry (HKAPI), an organization that represents the innovative pharmaceutical industry in Hong Kong and Macau, weighs in…
See our Cookie Privacy Policy Here